Thus, our study demonstrated that GPR43 can be coupled to the PKC-PLC pathway, suggesting that antagonists targeting the Gαq signalling can be clinically effective in the improvement of podocyte insulin resistance. This evidence concerns the gene FFAR2 and Insulin resistance.